← Banking With Billy News

Alumis plans a Q4 NDA filing for envudeucitinib in moderate-to-severe plaque psoriasis, a key regulatory step. The biotech also expects topline Phase 2b SLE dat

BWB News TV • 2026-08-13 20:16 UTC • By Billy Odell Tucker-Robinson
Alumis plans a Q4 NDA filing for envudeucitinib in moderate-to-severe plaque psoriasis, a key regulatory step. The biotech also expects topline Phase 2b SLE dat
Alumis plans a Q4 NDA filing for envudeucitinib in moderate-to-severe plaque psoriasis, a key regulatory step. The biotech also expects topline Phase 2b SLE data in Q3 alongside its Q2 results.
Share this article
𝕏 X / Twitter Facebook LinkedIn WhatsApp
📚 More from Billy’s World
📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly